Showing results (51-60 of 152) with videos related to
Sort By:
Pageof 16
Hepatology (Baltimore, Md.)|April 8, 2015
Ledipasvir-sofosbuvir plus ribavirin for patients with genotype 1 hepatitis C virus previously treated in clinical trials of sofosbuvir regimensDavid Wyles, Paul Pockros, Giuseppe Morelli, et al.Journal of Hepatology|February 27, 2013
A phase 2B study of MK-7009 (vaniprevir) in patients with genotype 1 HCV infection who have failed previous pegylated interferon and ribavirin treatmentEric Lawitz, Maribel Rodriguez-Torres, Albrecht Stoehr, et al.Hepatology (Baltimore, Md.)|April 3, 2026
A randomized, open-label, Phase 2a study to assess the safety, pharmacodynamics, and pharmacokinetics of YAQ007 versus rifaximin in cirrhosisMaria Pilar Ballester, Juan Antonio Carbonell-Asins, Ahmed Elshabrawi, et al.Liver International : Official Journal of the International Association for the Study of the Liver|January 31, 2024
Safety, pharmacokinetics and pharmacodynamics of obeticholic acid in subjects with fibrosis or cirrhosis from NASHNaim Alkhouri, Carl LaCerte, Jeffrey Edwards, et al.Clinical Pharmacokinetics|March 10, 2018
Pharmacokinetics and Safety of Velpatasvir and Sofosbuvir/Velpatasvir in Subjects with Hepatic ImpairmentErik Mogalian, Diana M Brainard, Anu Osinusi, et al.The Journal of Infection|September 24, 2014
Exploratory trial of ombitasvir and ABT-450/r with or without ribavirin for HCV genotype 1, 2, and 3 infectionEric Lawitz, Greg Sullivan, Maribel Rodriguez-Torres, et al.Antimicrobial Agents and Chemotherapy|April 16, 2014
Randomized, placebo-controlled, single-ascending-dose study of BMS-791325, a hepatitis C virus (HCV) NS5B polymerase inhibitor, in HCV genotype 1 infectionKaren D Sims, Julie Lemm, Timothy Eley, et al.The Lancet. Gastroenterology & Hepatology|October 13, 2024
Denifanstat for the treatment of metabolic dysfunction-associated steatohepatitis: a multicentre, double-blind, randomised, placebo-controlled, phase 2b trialRohit Loomba, Pierre Bedossa, Katharine Grimmer, et al.Journal of Hepatology|February 27, 2013
A phase 2a trial of 12-week interferon-free therapy with two direct-acting antivirals (ABT-450/r, ABT-072) and ribavirin in IL28B C/C patients with chronic hepatitis C genotype 1Eric Lawitz, Fred Poordad, Kris V Kowdley, et al.Hepatology (Baltimore, Md.)|February 22, 2017
Sofosbuvir-velpatasvir-voxilaprevir with or without ribavirin in direct-acting antiviral-experienced patients with genotype 1 hepatitis C virusEric Lawitz, Fred Poordad, Jennifer Wells, et al.Pageof 16